

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 19134

Title: Novel therapeutic agents in the treatment of metastatic colorectal cancer

Reviewer's code: 02438889

Reviewer's country: Germany

Science editor: Ya-Juan Ma

Date sent for review: 2015-05-07 20:12

Date reviewed: 2015-09-11 18:33

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This is a progress report with perspectives but not a systematic review. If you had written a systematic review you could probably do a meta-analysis. The conflict of interest is not given and is missing. You need to add a glossary since many abbreviations are not explained. You should also explain with more details the mechanisms of action of the new drugs. There are a few spelling mistakes; Cetuximab:failed on oxaliplatin not failed an oxaliplatin; RAS testing not RAS resting. The table should have a title not a legend.